Drug Profile
SAR 101099
Alternative Names: SAR101099Latest Information Update: 29 Feb 2012
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Urotensin II antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic nephropathies
Most Recent Events
- 08 Feb 2012 Discontinued - Phase-I for Diabetic nephropathies in Europe (unspecified route)